MA71714A - Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées - Google Patents

Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées

Info

Publication number
MA71714A
MA71714A MA71714A MA71714A MA71714A MA 71714 A MA71714 A MA 71714A MA 71714 A MA71714 A MA 71714A MA 71714 A MA71714 A MA 71714A MA 71714 A MA71714 A MA 71714A
Authority
MA
Morocco
Prior art keywords
aimp2
mir
optionally
methods
target sequence
Prior art date
Application number
MA71714A
Other languages
English (en)
French (fr)
Inventor
Jin Woo Choi
Kyunghwa BAEK
Original Assignee
Generoath Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generoath Co., Ltd. filed Critical Generoath Co., Ltd.
Publication of MA71714A publication Critical patent/MA71714A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA71714A 2020-09-30 2021-09-30 Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées MA71714A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085950P 2020-09-30 2020-09-30
PCT/IB2021/059017 WO2022070141A1 (en) 2020-09-30 2021-09-30 METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF
EP21874707.9A EP4221759A4 (en) 2020-09-30 2021-09-30 METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE OF MIR-142 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
MA71714A true MA71714A (fr) 2025-05-30

Family

ID=80949780

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71714A MA71714A (fr) 2020-09-30 2021-09-30 Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées

Country Status (9)

Country Link
US (1) US20230374092A1 (https=)
EP (1) EP4221759A4 (https=)
JP (1) JP2023544141A (https=)
KR (1) KR20230079267A (https=)
CN (1) CN116507370A (https=)
AU (1) AU2021354996A1 (https=)
CA (1) CA3192710A1 (https=)
MA (1) MA71714A (https=)
WO (1) WO2022070141A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459529B2 (en) * 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
KR101067816B1 (ko) * 2007-11-09 2011-09-27 (주)네오믹스 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
KR101749138B1 (ko) * 2015-10-07 2017-06-20 원광대학교산학협력단 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
US10716866B2 (en) * 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102349061B1 (ko) * 2019-03-15 2022-01-10 주식회사 제너로스 생착능이 증가된 줄기세포의 제조 방법
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터

Also Published As

Publication number Publication date
CA3192710A1 (en) 2022-04-07
WO2022070141A1 (en) 2022-04-07
CN116507370A (zh) 2023-07-28
KR20230079267A (ko) 2023-06-05
AU2021354996A9 (en) 2023-04-27
US20230374092A1 (en) 2023-11-23
JP2023544141A (ja) 2023-10-20
EP4221759A1 (en) 2023-08-09
AU2021354996A1 (en) 2023-04-20
EP4221759A4 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
MA71714A (fr) Méthodes de traitement de maladies neuronales à l'aide d'aimp2-dx2 et éventuellement d'une séquence cible de mir-142 et compositions associées
EP4267582A4 (en) METHODS AND MODIFIED NUCLEOSIDES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
EP3980069A4 (en) METHODS OF TREATMENT OF SPLENOMEGALY
EP4087878A4 (en) MUSCLE-TARGETED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
EP3877045A4 (en) TREATMENT OF DRUG-RESISTANT HYPERTENSION ASSOCIATED WITH IMPAIRED LEFT VENTRICULAR FUNCTION AND BRADYCARDIA USING A PACEMAKER
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP4228687A4 (en) VIRUS-INSPIRED COMPOSITIONS AND METHODS FOR REROUTERING PRE-EXISTING IMMUNE RESPONSES AND THEREBY FOR THE TREATMENT OF CANCER
EP3976053A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC DISEASES
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP4050997A4 (en) TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3266951A1 (en) Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
EP4100127A4 (en) METHOD FOR TREATING SCLERODERMA AND RELATED DISEASES
EP4460524A4 (en) Compositions and methods for treatment of thyroid eye disease
EP3440045A4 (en) PREVENTING, TREATING AND REVERSING DISEASES USING THERAPEUTICALLY ACTIVE AMOUNTS OF DICARBONIC ACID COMPOUNDS
EP4037696A4 (en) Compositions and methods for treating alzheimer's disease
EP4192494A4 (en) Methods for treating and preventing cytomegalovirus infection
EP4213855A4 (en) TREATMENT OF NF-KB-MEDIATED DISEASES
EP4017490A4 (en) Compounds and methods for treating oxalate-related diseases
EP4313147A4 (en) Methods for treating cancer with anti-CTLA4 antibodies
EP4371131A4 (en) ASSESSMENT OF DISEASE TREATMENT
EP4384220A4 (en) Compositions and methods for treatment of cancer
EP4192457A4 (en) Compositions and methods for treating or preventing disease associated with beta coronavirus infection
EP4295151A4 (en) METHODS FOR STRATIFICATION AND TREATMENT OF CORONAVIRUS INFECTIONS
EP3958892A4 (en) METHOD OF TREATMENT OF LIVER DISEASE